Lumenis sues founder Shimon Eckhouse for $30m

Lumenis alleges that immediately after Eckhouse was ousted, he founded Syneron Medical to copy Lumenis' flagship product.

Lumenis (Nasdaq: LUME) today filed a $30 million lawsuit against Dr. Shimon Eckhouse with the Tel Aviv District Court. Eckhouse founded and controlled Lumenis from late 1991 through 1999. Lumenis develops devices for esthetic medical treatments.

Lumenis alleges that Eckhouse and other defendants stole trade secrets and copied technologies from the company.

Lumenis alleges that Syneron Medical, founded by Eckhouse and the other defendants in July 2000, "was established with the purpose of creating a product essentially similar to the plaintiffs products and selling it through the plaintiffs distributors to its customers, by misappropriating its trade secrets and breaching fiduciary duties of the defendants and/or Syneron and/or some of them to the plaintiff by copying the plaintiffs technology and by being unjustly enriched at the plaintiffs expense.

Lumenis claims that Eckhouse succeeded, through Syneron, in manufacturing a product identical to the product manufactured by the plaintiff.

The short time following Dr. Eckhouses retirement from the plaintiff until the completion of the manufacture of the copied product clearly shows the unlawful cynical exploitation taken with respect to information which was deposited in trust into his hands by way of attempting to cause actual damage to the plaintiff following his removal from the management of its interests and by causing image and financial damage to the plaintiffs business from which the plaintiff is still today finding difficult to rehabilitate itself.

A letter of defense has not yet been filed.

Published by Globes [online] - - on September 12, 2002

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments

Twitter Facebook Linkedin RSS Newsletters Capital  Markets Conference 2017